Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Belhaven Biopharma Initiates a Pivotal Biocomparability Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Nasdepi(R) vs. Epinephrine Intramuscular Injections

Belhaven's Investigational New Drug (IND) Application Receives FDA Authorization to Proceed

RALEIGH, NORTH CAROLINA / ACCESS Newswire / October 8, 2025 / Belhaven Biopharma, a leader in developing innovative intranasal products for emergency use, today announced that the U.S. Food and Drug Administration ("FDA" or the "Agency") has accepted their IND application for Nasdepi® (BBP01), a novel, investigational nasal powder epinephrine formulation, designed as a needle-free alternative for the emergency treatment of anaphylaxis. This key milestone marks the next step in Nasdepi's development, allowing Belhaven Biopharma to initiate the pivotal biocomparable study designed to demonstrate its pharmacokinetics, pharmacodynamics, and safety, compared to established intramuscular (IM) epinephrine injections and autoinjectors. This follows two clinical trials that were performed under Health Canada and submitted to FDA in the IND.

The trial is a randomized, crossover design to compare Nasdepi 4.5 mg nasal powder against 0.3 mg IM epinephrine manual injection and 0.3 mg epinephrine autoinjector. The study's primary objective is to determine whether Nasdepi achieves comparable epinephrine pharmacokinetic parameters including area under the curve, maximum concentration, and time to peak concentration. Pharmacodynamic measurements will be performed, including blood pressure and heart rate, to confirm the expected physiological response is achieved and in safe and tolerated ranges.

"Millions of people at risk of anaphylaxis still hesitate to carry or have access to epinephrine autoinjectors due to cost, fear, or difficulty of use," said Scott Lyman, CEO of Belhaven Biopharma. "Our goal with Nasdepi is to make epinephrine more accessible and easier to administer in critical moments. This study is a significant step toward delivering a needle-free, heat stable, and reliable treatment option that could transform emergency allergy care and provide a viable treatment where epinephrine is not currently available to patients."

About Belhaven Biopharma

Belhaven Biopharma is a clinical-stage pharmaceutical research company specializing in developing life-saving medications delivered quickly, effectively, and painlessly with a simple, dry powder, single-use nasal device. They are at the forefront of developing nasal dry powder epinephrine, which is revolutionizing emergency-use epinephrine delivery and expanding global access. Nasdepi, Belhaven's lead program, is the first dry powder nasal device for treating life-threatening allergic reactions. For more information, please visit www.belhavenbio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" based on our management's current beliefs, assumptions, and available information. These statements, which are not historical facts, include expectations regarding financial performance, business plans, clinical and preclinical development, timing and outcomes of trials, regulatory approvals, product potential, competitive position, and market opportunities. Words such as "believe," "may," "will," "anticipate," "intend," and "expect" identify such statements. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially, including those related to product development, regulatory processes, funding, commercialization, market acceptance, intellectual property, third-party manufacturing, competition, and management retention. These statements reflect current expectations, but given the rapidly changing environment, new risks may emerge and outcomes may differ. We do not undertake any obligation to update forward-looking statements to reflect new information or future events.

Contact Information

Janie Mackenzie
Vice President of Public Relations
janie@ascendantgroupbranding.com
267.969.4992

.

SOURCE: Belhaven Biopharma



View the original press release on ACCESS Newswire

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.